Electronic ISSN 2287-0237

VOLUME

CHALLENGES IN PRODUCTION OF ALZHEIMER’S TRACER C-11 PIB

FEBRUARY 2015 - VOL.9 | REVIEWS ARTICLE

Beta-amyloid plaques and neurofibrillary tangles have been known as the neuro- pathological hallmarks of Alzheimer’s disease. 11C Pittsburgh Compound B (PiB) ([C-11]PiB) is the first successful and well-studied radiopharmaceutical for Positron Emission Tomography (PET) imaging of beta-amyloid deposition in the brain. Although [C-11]PiB has been used in western countries since 2002, Wattanosoth Hospital was the only center with the capacity to produce [C-11]PiB in South-East Asia in 2012. This article describes briefly the challenges the PET radiopharmaceutical team at Wattanosoth Hospital have been facing in the production of [C-11]PiB. It also provides a brief protocol used here for production of [C-11]PiB.

Keywords:

C-11 PiB, Pittsburgh Compound, Alzheimer’s, PET in neurology, beta amyloid tracer

MEDIA
Figure 1:
C-11 PRO2 autosynthesis module in a hot cell for [C-11]PiB synthesis at Wattanosoth Hospital.
Figure 2:
Main chemical reaction for [C-11]PiB synthesis
Figure 3:
PiB-PET image in normal subject shows no accumulate of beta-amyloid over the cortex area.
Figure 4:
FDG-PET and PiB-PET image in Alzheimer’s dementia patient. The FDG-PET reveals hypometabolic activity over bilateral parietal lobe, posterior cingulate and precuneus (A, B), whereas PiB-PET shows accumulation of beta-amyloid over the cortex areas (C, D).
SEARCH VOLUME & NUMBER
GO
RECENT VOLUME & NUMBER